Investor Presentation • Mar 16, 2016
Investor Presentation
Open in ViewerOpens in native device viewer
Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Monna Lisa Touch
Cyber TM 200
Discovery Pico
Motus AX
| \$ l b l k f d l l b d h h ( l l ) i i i G 2 0 1 9 t t o a m a r e o r m e c a a s e r s y e n u s e r o u g m o n s , |
||||||||
|---|---|---|---|---|---|---|---|---|
| 2 0 1 3 |
2 0 1 4 |
C A G % R |
||||||
| 2 0 1 4 2 0 1 9 - |
||||||||
| 7 5 8 |
8 1 3 |
1 2 1 9 |
% 8 4 , |
|||||
| 8 9 5 |
0 2 1 4 |
2 0 9 7 |
% 1 5 4 , |
|||||
| 2 0 9 |
2 4 4 |
6 2 3 |
2 0 % 7 , |
|||||
| 9 9 |
1 1 5 |
2 4 7 |
1 6 % 5 , |
|||||
| 1 9 6 1 |
2 1 9 5 |
4 1 8 5 |
1 3 8 % , |
|||||
| 2 0 1 9 |
Global market for medical lasers by region, through 2019 (\$ millions)
| k M S t t a r e e g m e n |
2 0 1 3 |
2 0 1 4 |
2 0 1 9 |
% C A G R |
|
|---|---|---|---|---|---|
| 2 0 1 4 2 0 1 9 - |
|||||
| d d U S C a n a n a a |
9 0 2 |
1 0 0 8 |
1 8 7 0 |
1 3 2 % , |
|
| E u r o p e |
5 7 9 |
6 4 7 |
1 2 0 8 |
% 1 3 3 , |
|
| f i i i A P s a a c c |
3 5 2 |
3 9 9 |
8 4 9 |
% 1 6 3 , |
|
| h O t e r |
2 8 1 |
1 4 1 |
2 8 5 |
2 8 % 1 , |
|
| l T t o a |
9 6 1 1 |
2 9 1 5 |
8 4 1 5 |
3 8 % 1 , |
| l B V a e y u |
l b l G M o a a |
k ( l i E U R M t r e |
( ) C A G R % |
||
|---|---|---|---|---|---|
| 2 0 1 3 |
2 0 1 6 |
2 0 2 0 |
2 0 1 3 2 0 1 6 - |
2 0 1 6 2 0 2 0 - |
|
| C i t t n u g |
2 4 0 8 |
3 0 1 4 |
3 9 6 5 |
7 8 , |
7 1 , |
| l d d i i W B e n g a n r a n g z |
1 2 4 9 |
1 6 0 5 |
2 2 3 1 |
8 7 , |
8 6 , |
| f d h S O t t t t u r a c e r e a m e n a n e r |
5 0 |
6 3 |
8 6 |
8 3 , |
8 1 , |
| l T t o a |
3 7 0 7 |
4 6 8 2 |
6 2 8 2 |
8 1 , |
7 6 , |
High –Tech laser photonics Group
Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications
Know-how based on 35 years stratification of multidisciplinary experience
2015: Consolidated Revenues of €218 mln, up 21% YoY
965 employees
Global positioning
Combine High tech laser source development with flexible production facilities in high growth areas
Technological and clinical innovation improving performance andbroadening the application scope of our laser systems
Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser- tissue interaction
Broadening Mona Lisa Touch Clinical studiesNew Pico second laser platform Clinical studies on cutaneous ulcers Painless laser hair removalPatents developmentIncreased power of RF laser sourcesInnovative applications for mid power laser systems
| / E 0 0 0 u r o |
/ / 3 2 1 1 1 4 |
/ / 3 2 1 1 1 5 |
% V a r. |
||
|---|---|---|---|---|---|
| d d i t n a e u u |
|||||
| R e v e n u e s |
1 8 0 0 0 9 |
1 0 0 0 % , |
2 1 7 6 7 0 |
1 0 0 0 % , |
2 0 9 % , |
| i G r o s s m a r g n |
8 8 9 1 4 |
% 4 5 5 , |
9 6 3 8 1 |
% 4 4 2 , |
% 1 7 7 , |
| E B I T D A |
1 7 9 6 3 |
0 0 % 1 , |
2 5 6 6 6 |
8 % 1 1 , |
2 9 % 4 , |
| E B I T ( * ) |
1 5 3 0 1 |
% 8 5 , |
2 1 4 9 9 |
% 9 9 , |
% 4 0 5 , |
| P I t ( ) r e a n c o m e x |
2 0 9 4 4 |
3 6 % 1 , |
2 3 1 1 3 |
0 6 % 1 , |
3 % 5 - , |
| i N t ( * ) e n c o m e |
1 6 5 2 0 |
9 2 % , |
1 4 3 7 1 |
6 6 % , |
1 3 0 % - , |
| h N I t e n c o m e p e r s a r e |
3 4 2 , |
2 9 8 , |
(*) 2014 Non recurring: +1,5 mln of euros. 2014 EBIT% w/o non recurring: 7,7% and var% 15/14 adj.: +55%(**) 2014 Total one time and non recurring: +9,0mln of euros on pretax income and var% 15/14 adj.: +65%(***) 2014 Total one time and non recurring: +8 mln of euros on net income and var% 15/14 adj.: +68%
| / 0 0 0 E r o u |
/ / 3 1 1 2 1 4 |
/ / 3 1 1 2 1 5 d d i t u n a u e |
% V a r. |
|---|---|---|---|
| l T t t t o a n o n r r e n a s s e s c u |
6 1 7 7 5 |
9 6 6 7 7 |
8 % 5 |
| k i i l N W C t t e o r n g a p a |
4 9 5 0 1 |
5 9 8 6 1 |
% 2 1 |
| f l i i i i N t t e n a n c a p o s o n |
4 7 1 1 6 |
2 9 8 1 5 |
% 3 7 - |
| l b l i i i i L t t o n g e r m a e s |
7 8 5 6 |
7 9 0 4 |
% 1 |
| i N E t t e q u y |
0 3 6 1 5 5 |
9 3 9 1 7 5 |
9 % 1 |
| i l l d N t t e c a p a e m p o y e |
1 0 3 4 2 0 |
1 4 9 7 2 4 |
% 4 5 |
| k l l i i N W C t t e o r n g a p a o n s a e s |
2 7 % |
2 8 % |
|
| O C R E / ( l l d ) i E B I T N t t e c a p a e m p o y e |
% 1 5 |
% 1 4 |
|
| C a p e x |
8 4 7 7 |
8 2 3 4 |
Euro
| k h l d 's h * S i E t t o c o e r q u y p e r s a r e |
3 5 |
|---|---|
| / k l d i j. P B V A r c e o o a u e |
1, 1 8 |
| / ( ) V I 8 % I E E B T 5 E B T |
6, 3 5 |
| / ( ) l l E V S 8 5 % S a e s a e s |
0, 6 4 |
| l. k E E M C t n a r e a p |
1 9 7, 8 @ € 4 1, 0 0 |
| f l i i i i N t t e n a n c a p o s o n |
/ / 2 9, 8 @ 3 2 1 1 1 5 |
| / i i l i l F t t t n a n c a n e s m e n s m e r m v |
/ / @ 1 0, 6 3 1 1 2 1 5 |
| k l f h 1, 0 C M t a r e v a u e o m m y n o s u r e s a r e s |
\$ 3 8, 0 @ 2, 2 6 4 / ( ) d E U 1, 1 1 u r o s = |
| l i E V t n e r p r s e a u e |
1 1 9, 3 |
| k h l d 's f i i i i S E t t t t o c o e r q u y n e o m n o r e s, * ( ) h h k l i C t t t w y n o s u r e s a r e s a m a r e v a u e |
1 6 7, 5 |
| D 3 1 2 0 1 5 t , e c s |
ic Pr e |
Re ve nu e |
% Va r. Re ve nu e |
E B I T |
% E B I T |
C M K. a p. |
E V |
/ le S E V a s |
/ E V E B I T |
/ k P Bo o lu Va e |
|---|---|---|---|---|---|---|---|---|---|---|
| / d l h i A i M t t e c a e s e c |
||||||||||
| S y n e r o n |
\$ 8, 1 6 |
\$ 2 7 7. 8 4 9 |
9 % |
\$ ( ) 6. 4 5 9 |
-2 % |
\$ 3 0 6. 7 1 0 |
\$ 2 2 0. 0 5 4 |
0, 7 9 |
n. a. |
1, 4 7 |
| l i Z t e q |
\$ 2 3, 2 3 |
\$ 2 6 5 5. 4 1 |
6 % 4 |
\$ 3. 6 9 4 |
% 1 |
\$ 9 2 0. 0 4 4 |
\$ 8 6 7 1. 7 1 |
3, 4 1 |
2 3 9 9 5, |
0 7, 4 |
| C t u e r a |
\$ 1 2, 6 6 |
\$ 9 4. 7 6 1 |
2 1 % |
\$ ( ) 4. 5 2 1 |
-5 % |
\$ 1 6 9. 0 2 0 |
\$ 1 2 0. 6 1 3 |
1, 2 7 |
n. a. |
3, 3 8 |
| i l B o a s e |
\$ 1, 2 1 |
\$ 4 8. 4 7 5 |
2 % |
\$ ( ) 1 9. 9 1 5 |
-4 1 % |
\$ 6 9. 3 1 0 |
\$ 5 7. 5 7 0 |
1, 1 9 |
n. a. |
2, 7 8 |
| C n o s r e y u |
\$ 4 2, 2 6 |
\$ 3 3 9. 4 6 2 |
1 6 % |
\$ 2 6. 3 2 1 |
8 % |
\$ 1. 0 2 0. 0 0 0 |
\$ 8 9 4. 1 1 4 |
2, 6 3 |
3 3, 9 7 |
2, 5 2 |
| d i l I t n u s r a |
||||||||||
| h I P G P i C t o o n s o. c |
\$ 9 0, 9 4 |
\$ 9 0 1. 2 6 5 |
1 7 % |
\$ 3 4 2. 0 4 3 |
3 8 % |
\$ 4. 9 1 0. 0 0 0 |
\$ 4. 2 2 0. 8 8 4 |
4, 6 8 |
1 2, 3 4 |
3, 8 9 |
| f i i R S o n- n a r |
\$ 2 3, 4 8 |
\$ 5 0 9. 7 1 7 |
-4 % |
\$ 5 6. 9 7 9 |
1 1 % |
\$ 6 8 3. 3 2 0 |
\$ 5 1 2. 5 9 0 |
1, 0 1 |
9, 0 0 |
1, 2 4 |
| l. ( ) E E 1 n. |
€ 4 1, 0 0 |
€ 2 1 7. 6 7 0 |
2 1 % |
€ 2 1. 4 9 9 |
1 0 % |
€ 1 9 7. 7 9 9 |
€ 1 1 9. 3 2 1 |
0, 6 4 |
6, 5 3 |
1, 1 8 |
(1) EV and multiplies as for previous slide
Enrico ROMAGNOLI Investor Relations Managertel. +39 055-8826807E-mail: [email protected]
Bianca FERSINI MASTELLONI Financial CommunicationTel. +39 06-6797849 / +39 06-69923324E-mail: [email protected]
Silvia MARONGIUPress officeTel. +39 06-6797849 / +39 06-69923324E-mail: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.